RhumbLine Advisers’s Neurogene NGNE Stock Holding History
Bought
Maintained
Sold
Other funds holding NGNE
BBA
RhumbLine Advisers's NGNE Position: Q3 2026 in Review
RhumbLine Advisers increased its Neurogene (NGNE) stake by 28% in Q3 2026, buying an estimated $140K and bringing the position to 18,074 shares worth $503K. The position accounts for ﹤0.01% of the portfolio, ranked #2726.
RhumbLine Advisers first reported a position in NGNE in Q2 2020 and has held it in 18 quarters since. The position peaked at $603K in Q3 2024. 131 funds tracked by Wall St. Rank hold NGNE as of Q3 2026.
- RhumbLine Advisers held 18,074 shares of Neurogene worth $503K as of Q3 2026.
- RhumbLine Advisers bought 3,921 Neurogene shares in Q3 2026, an estimated $140K.
- Neurogene made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #2726 holding.
- RhumbLine Advisers first reported a position in Neurogene in Q2 2020 and has held it in 18 quarters since.
- RhumbLine Advisers's Neurogene position peaked at $603K in Q3 2024.
- 131 funds tracked by Wall St. Rank held Neurogene as of Q3 2026.
Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.